1. Pink Sheet
  2. >>Geography
  3. >>Europe

Nitrosamine Concerns Spur Precautionary Testing Of Rifampicin In EU

Probe Into Presence Of Nitrosamine Impurity In Rifampicin Medicines Is Ongoing

 
• By Vibha Sharma

National regulators throughout the EU will ask manufacturers of rifampicin-containing medicines to check their products for nitrosamine impurities before they are released for sale.

Rifampicin capsule for treatment tuberculosis and leprosy. Antibiotic resistance of tuberculosis (TB). Antituberculosis drug. Red pills produce reddish coloration of urine, sweat, sputum, and tears.
Rifampicin is among a wide array of drugs in which nitrosamine impurities have been found • Source: Shutterstock

Regulators in the EU have introduced new testing requirements for all medicines containing the antibiotic drug, rifampicin, to address concerns that they may be contaminated with cancer-causing nitrosamine impurities.

Rifampicin is a first-line treatment for tuberculosis and is also used for treating several other serious infections, including blood infections...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

More from Geography